We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
-11.11%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$7.07B
AUM Growth
-$1.54B
Cap. Flow
-$210M
Cap. Flow %
-2.97%
Top 10 Hldgs %
34.72%
Holding
187
New
10
Increased
57
Reduced
82
Closed
15

Top Buys

Rank Stock Value
1
ISRG icon
Intuitive Surgical
ISRG
+$67.9M
2
PFE icon
Pfizer
PFE
+$40.2M
3
CLDX icon
Celldex Therapeutics
CLDX
+$26.9M
4
HRMY icon
Harmony Biosciences
HRMY
+$26M
5
CRL icon
Charles River Laboratories
CRL
+$25.6M

Top Sells

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$100M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$81.4M
3
ABBV icon
AbbVie
ABBV
+$47.5M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$47.2M
5
BMY icon
Bristol-Myers Squibb
BMY
+$45.9M

Sector Composition

Rank Sector Weight
1 Healthcare 98.26%
2 Industrials 0.38%
3 Energy 0.03%
4 Communication Services 0.01%
5 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PFE icon
51
Pfizer
PFE
$142B
$43.8M 0.62%
835,684
+789,184
+1,697% +$40.2M
HALO icon
52
Halozyme
HALO
$9.19B
$42.7M 0.6%
971,300
-52,900
-5% -$2.29M
ABMD
53
DELISTED
Abiomed Inc
ABMD
$42M 0.59%
169,509
+19,331
+13% +$5.22M
IDXX icon
54
Idexx Laboratories
IDXX
$44.7B
$40.6M 0.57%
115,773
-2,037
-2% -$831K
TMO icon
55
Thermo Fisher Scientific
TMO
$196B
$39M 0.55%
71,818
-815
-1% -$449K
SILK
56
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$38.1M 0.54%
1,047,286
+1,719
+0.2% +$62.5K
GMED icon
57
Globus Medical
GMED
$10.5B
$36.9M 0.52%
656,681
-88,573
-12% -$5.82M
IQV icon
58
IQVIA
IQV
$34.1B
$36.6M 0.52%
168,598
+9,478
+6% +$2.06M
LEGN icon
59
Legend Biotech
LEGN
$4.52B
$34.7M 0.49%
630,439
-29,630
-4% -$1.25M
OM icon
60
Outset Medical
OM
$73.8M
$34.6M 0.49%
155,115
+20,638
+15% +$8.88M
HRMY icon
61
Harmony Biosciences
HRMY
$1.96B
$34.2M 0.48%
702,068
+577,107
+462% +$26M
VEEV icon
62
Veeva Systems
VEEV
$32.1B
$33.4M 0.47%
168,776
+8,175
+5% +$1.5M
ALGN icon
63
Align Technology
ALGN
$12.6B
$32M 0.45%
135,240
-6,111
-4% -$1.88M
AXSM icon
64
Axsome Therapeutics
AXSM
$11.7B
$31.3M 0.44%
817,141
+97,659
+14% +$3.09M
EXAS
65
DELISTED
Exact Sciences
EXAS
$29.9M 0.42%
758,023
+38,720
+5% +$2.07M
BAX icon
66
Baxter International
BAX
$11.5B
$29.4M 0.42%
457,819
-32,061
-7% -$2.33M
ADPT icon
67
Adaptive Biotechnologies
ADPT
$3.5B
$28.6M 0.4%
3,539,055
+393,762
+13% +$3.46M
ZBH icon
68
Zimmer Biomet
ZBH
$17.4B
$28M 0.4%
266,087
-4,647
-2% -$551K
ESPR
69
DELISTED
Esperion Therapeutics
ESPR
$26.9M 0.38%
4,235,264
-63,900
-1% -$362K
HZNP
70
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$26.9M 0.38%
337,434
-7,666
-2% -$726K
ACCD
71
DELISTED
Accolade Inc
ACCD
$26.9M 0.38%
3,634,886
+253,379
+7% +$2.22M
AUPH icon
72
Aurinia Pharmaceuticals
AUPH
$1.98B
$26.8M 0.38%
2,671,413
+265,588
+11% +$2.97M
PACB icon
73
Pacific Biosciences
PACB
$422M
$26.3M 0.37%
5,961,229
+1,079,477
+22% +$6.56M
ATRC icon
74
AtriCure
ATRC
$1.77B
$26.2M 0.37%
641,896
+43,291
+7% +$2.05M
COO icon
75
Cooper Companies
COO
$13.9B
$25.5M 0.36%
325,916
-6,948
-2% -$615K
1 2
3
4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q2 2022 Portfolio in Review

As of Q2 2022, Bellevue Group held 187 positions worth $7.07B, down 18% from $8.61B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Bellevue Group's Q2 2022 filing shows 10 new, 57 increased, 82 reduced and 15 closed positions. Its largest new stake was Celldex Therapeutics: 925,000 shares worth $24.9M. The largest sale was Elevance Health, an estimated $100M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 98% a quarter earlier, followed by Industrials and Energy.

  • Bellevue Group's largest Q2 2022 buy was Celldex Therapeutics: 925,000 shares worth $24.9M.
  • Bellevue Group added most to Intuitive Surgical in Q2 2022, an estimated $67.9M increase.
  • Bellevue Group's biggest Q2 2022 reduction was Elevance Health, cutting an estimated $100M.
  • Bellevue Group fully exited Dentsply Sirona in Q2 2022, selling an estimated $7.83M.
  • Bellevue Group's ten largest holdings make up 35% of its $7.07B portfolio in Q2 2022.
  • Bellevue Group opened 10 new positions and closed 15 in Q2 2022.
  • Bellevue Group's portfolio value fell 18% quarter-over-quarter to $7.07B.

Based on Bellevue Group's 13F filing for Q2 2022, filed 11 Aug 2022.